Antiretroviral Agents: Nucleoside Reverse Transcriptase Inhibitors

Quick Menu / Table of Contents
Introduction	Principles	Management	NRTI Info	NNRTI Info
PI Info	Fusion Inhibitors	Drug Summary	Investigational	Adherence
Lab Evaluation	Resistance Tests	PEP	Antiretroviral Tables	OI Prevention
Vaccinations	TB Therapy	Hepatitis Therapy	OI Diagnosis	OI Therapy
Bibliography		Links		Palliative Therapy

Truvada
emtricitabine + tenofovir

Detailed Prescribing Information

October 2005

Truvada A combination of tenofovir + emtricitabine Approved 8-2-2004
Forms Available	300 mg tenofovir / 200 mg emtricitabine in tablet form
Dosing	1 tablet once a day with or without food
	Renal dosing	Dosing interval Ccr 30-49 cc/min	Dosing interval Ccr < 30 cc/min
		48 hours	Not recommended
	Hepatic dosing: very little data, but preliminary information suggests little effect on dosing.
Food dependence	None significant.
Adverse Effects	Same as tenofovir and emtricitabine (see above or click on the drug name)
Interactions	Same as tenofovir and emtricitabine (see above or click on the drug name)
Suggested lab follow-up	Monthly CBC for 3 months, then every 3 months if stable Consider monthly creatinine measurements in lean individuals or those with renal insufficiency.
Warning	Rare lactic acidosis and hepatic steatosis. Do not used fixed dose combination in persons with renal insufficiency. Severe acute exacerbations of chronic hepatitis B may be observed with sudden discontinuation of Truvada.
Contraindication	None
Suggested Usage	Do not use in combination with lamivudine, emtricitabine, Epzicom, Combivir, or Trizivir due to identical mechanism of action or duplication of emtricitabine dosing.
Complete prescribing information	Truvada Prescribing Info Also see http://www.truvada.com for further info as it becomes available.

Next Page

Click HERE for Key NRTI Information

or Antiretroviral Summary Information

Links to Antiretroviral Sections (click on anything)

Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI)

AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada | Atripla

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI)

efavirenz | nevirapine | delavirdine

Protease Inhibitors (PI) | Boosted Protease Inhibitors

Fusion Inhibitors

enfuvirtide

Quick Menu / Table of Contents
Introduction	Principles	Management	NRTI Info	NNRTI Info
PI Info	Fusion Inhibitors	Drug Summary	Investigational	Adherence
Lab Evaluation	Resistance Tests	PEP	Antiretroviral Tables	OI Prevention
Vaccinations	TB Therapy	Hepatitis Therapy	OI Diagnosis	OI Therapy
Bibliography		Links		Palliative Therapy

Updated 10.25.2005

1. Renal dosing information from: Ian R. McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18